1. Home
  2. AOMR vs ACIU Comparison

AOMR vs ACIU Comparison

Compare AOMR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AOMR

Angel Oak Mortgage REIT Inc.

HOLD

Current Price

$8.91

Market Cap

210.5M

Sector

Real Estate

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.51

Market Cap

244.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AOMR
ACIU
Founded
2018
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.5M
244.3M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
AOMR
ACIU
Price
$8.91
$2.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$11.08
$10.00
AVG Volume (30 Days)
151.5K
298.1K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
14.18%
N/A
EPS Growth
53.85
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
$1.38
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.96
$1.65
52 Week High
$10.14
$4.00

Technical Indicators

Market Signals
Indicator
AOMR
ACIU
Relative Strength Index (RSI) 64.94 51.75
Support Level $8.73 N/A
Resistance Level $9.33 $3.20
Average True Range (ATR) 0.23 0.12
MACD 0.08 0.04
Stochastic Oscillator 100.00 86.54

Price Performance

Historical Comparison
AOMR
ACIU

About AOMR Angel Oak Mortgage REIT Inc.

Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: